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Abstract
Introduction: The application of lidocaine to the nasal mucosal area corresponding to the sphenopalatine fossa
has been shown to be effective at extinguishing pain attacks in patients with a cluster headache. In this report, the
effectiveness of local administration of lidocaine on cluster headache attacks as a symptomatic treatment of this
disorder is discussed.
Cases presentation: A 22-year-old Turkish man presented with a five-year history of severe, repeated, unilateral
periorbital pain and headache, diagnosed as a typical cluster headache. He suffered from rhinorrhea, lacrimation
and ptosis during headaches. He had tried several unsuccessful daily medications. We applied a cotton tip with
lidocaine hydrochloride into his left nostril for 10 minutes. The ptosis responded to the treatment and the intensity
of his headache decreased.
Conclusion: Intranasal lidocaine is a useful treatment for the acute management of a cluster headache. Intranasal
lidocaine blocks the neural transmission of the sphenopalatine ganglion, which contributes to the trigeminal nerve
as well as containing both parasympathetic and sympathetic fibers.
Introduction
Cluster headache (CH) is defined as a paroxysmal, strictly
unilateral and very severe headache [1]. It is seen very
rarely with a prevalence of less than 0.1% [2]. Ptosis, mio-
sis, lacrimation, conjunctival injection, rhinorrhea and
nasal congestion are autonomic symptoms, which usually
accompany retro-orbital pain. CH can be categorized
into episodic and chronic forms. Various treatment mod-
alities have been tried in both the prevention and treat-
ment of CH [3-6]. The intranasal application of 10%
lidocaine to the nasal mucosa corresponding to the sphe-
nopalatine fossa has proved effective [3,6]. However, the
mechanism of lidocaine in treating the headache is
unknown. Here, we report a male patient suffering from
CH and severe ptosis that immediately resolved with
intranasal lidocaine application and discuss the possible
mechanism of lidocaine in treating CH.
Case presentation
A 22-year-old Turkish man presented with a five-year
history of intermittent daily headache centered on the
left retro-orbital and orbital side. The pain was unilateral
with a side shift only within the same bout. He experi-
enced four to twenty attacks a week from the beginning
of the bout, which resulted in severe social agitation. The
attacks started abruptly and usually peaked within five
minutes, without any aura or precipitating factors, and
lasted 30 minutes to 120 minutes. He suffered from rhi-
norrhea, lacrimation and ptosis during the headaches,
without any noted nausea, vomiting or photophobia. He
had previously used several daily medications unsuccess-
fully, such as verapamil 160 mg thrice daily, naproxen
500 mg thrice daily, ibuprofen 600 mg thrice daily, dex-
ketoprofen trometamol 25 mg twice daily, indomethacin
25 mg thrice daily, loratadine 5 mg daily and predniso-
lone 60 mg daily. Both general and neurological examina-
tions between attacks and hematological-biochemical
screenings were normal. He had neither significant past
medical history nor family history of headache.
On the day of a severe headache, an ophthalmological
examination of our patient revealed lacrimation, conjunc-
tival injection and ptosis without miosis. We measured
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tions to both light and near stimulation. As attacks
occurred without significant periods of remission, we
diagnosed our patient with chronic CH. We applied a
cotton tip with 2 mL of lidocaine hydrochloride and epi-
nephrine (Jetocaine, 20 mg lidocaine/0.025 mg epinephr-
ine) into the left nostril for 10 minutes. The ptosis
responded to the treatment and the intensity of his head-
ache decreased. The magnetic resonance (MR) images of
his brain and orbit and MR angiography of his brain and
carotid artery were within normal limits. In 12 months of
follow-up, he had six to ten attacks a week accompanied
by autonomic symptoms, whichr e s o l v e dw i t hi n t r a n a s a l
lidocaine application.
Discussion
CH is a type of primary headache characterized by severe,
unilateral trigeminal pain with cranial parasympathetic
autonomic symptoms involving oculocephalic functions
[3]. The estimated prevalence is less than one in 1,000 in
the general population and the disease affects men with a
sex ratio between two point five and seven point five to
one [2]. The diagnostic criteria of the International Head-
ache Society allow for the distinction of two main CH
s u b t y p e s ,n a m e l ya ne p i s o d i cf o r ma n dac h r o n i cf o r m
[1,4]. In the episodic form, attacks occur daily for some
weeks followed by a period of remission. In the chronic
form, attacks occur without significant periods of
remission.
The unilateral autonomic symptoms such as ptosis,
miosis, lacrimation, conjunctival injection, rhinorrhea
and nasal congestion are lateralized to the pain during
the pain attack, and indicate parasympathetic hyperactiv-
ity and sympathetic impairment [4,6].
CH attacks are extremely painful and have a very rapid
onset and a very short duration. Acute therapy aims to
abort individual attacks. Treatment should therefore be
able to resolve or significantly reduce pain and accompa-
nying autonomic symptoms. Acute therapy for CH
includes oxygen inhalation and administration of ergots,
triptans, analgesics and intranasal local anesthetic agents
[4-7]. However, currently there is no specific therapy to
relieve the symptoms.
Practitioners have used lidocaine as an acute treatment
option for many types of headache by suppository, intra-
muscular, intravenous and nasal routes. Lidocaine 4%
application in the sphenopalatine fossa may offer the fast-
est relief of any known agent [3,8,9]. The sphenopalatine
ganglion (SPG) resides just posterior to and immediately
above the posterior tip of the middle turbinate, beneath
the nasal mucosa at a depth of 1 mm to 9 mm. Intranasal
lidocaine is administered with the patient supine, with
the tip of the nose pointed vertically, and the head turned
slightly toward the side of the block. A cotton-tipped
applicator saturated with 4% lidocaine is inserted intrana-
sally and applied to the lateral posterior wall of the nasal
cavity. The application of lidocaine to the area corre-
sponding to the sphenopalatine fossa has been shown to
be effective at extinguishing pain attacks in patients with
CH. Robbins [7] reported the clinical features and results
of the treatment of 30 patients with CH who had tried
4% lidocaine solution as a nasal spray to abort the
attacks. Of these 30 patients, 27% of the patients reported
moderate relief, 27% obtained mild relief and 46% found
no relief from the lidocaine.
Costa et al. [3] conducted a placebo-controlled study in
nine CH patients on the effect of a 1 mL solution of 10%
lidocaine applied during nitroglycerine-precipitated CH
attacks, applying a cotton swab intranasally on both sides
in the area of the sphenopalatine fossa under anterior rhi-
noscopy. In all treated patients, the pain disappeared on
average within 37 minutes of lidocaine application. It has
been demonstrated that nasal congestion, rhinorrhea,
lacrimation and photophobia generally disappear with
pain, while conjunctival injection, miosis and ptosis are
resolved later [6]. In our case, following intranasal lido-
caine application, pain ceased first and then ptosis
resolved, as described in the literature. We encountered
no complications in our case and, to date, there is no
reported toxicity in the literature.
The mechanism for lidocaine in treating CH is
unknown. Lidocaine provides its anesthetic effect as a
sodium pump inhibitor. It is hypothesized that lidocaine
provides local anesthesia, blocking neural transmission of
the SPG, which may be important in CH pathophysiology
[9]. The SPG is a complex region, including sensory
fibers that contribute to the trigeminal nerve, as well as
both parasympathetic and sympathetic fibers. Therefore,
intranasal lidocaine may produce both sensory and para-
sympathetic nerve blockade. However, the mechanisms
by which these blockages occur are not clear.
Conclusion
CH attacks need a symptomatic treatment that has a
rapid onset of action. Intranasal lidocaine is a useful
treatment for the acute management of CH, because of
its rapid onset of action and comfortable self-adminis-
tration. Patients can learn this technique themselves in
order to relieve acute attacks while conventional therapy
is being optimized.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompany-
ing images. A copy of the written consent is available
for review by the Editor-in-Chief of this journal
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